GlobalData on MSN9d
Ascletis Pharma’s ASC30 oral tablet shows promise in obesity trial
Ascletis Pharma has reported positive topline outcomes from its US Phase Ia single ascending dose (SAD) study of the oral ...
ScienceAlert on MSN10d
Scientists May Have Discovered a Natural Alternative to Ozempic
Scientists may have identified a way to naturally regulate blood sugar levels and sugar cravings in a similar fashion to ...
Hosted on MSN1mon
MSD makes obesity play in up to $2bn deal for Hansoh’s GLP-1RA asset
Merck & Co (MSD) has entered an exclusive global licence agreement with China-based Hansoh Pharma for a preclinical oral small molecule glucagon-like peptide 1 receptor agonist (GLP-1RA ...
Nature8d
Inactivation and Activation of Liver Phosphorylase
epinephrine and glucagon rapidly increase the amount of active phosphorylase in pre-incubated liver slices 1,2. In order to study the nature of the change in the phosphorylase molecule ...
Discover Magazine8d
Ozempic and Other GLP-1s May Have Broader Health Benefits but Greater Risks
Learn more about a new study claiming that GLP-1s could be used to treat cognitive conditions like dementia, but may pose a risk to other vital organs.
Seeking Alpha1y
NMTRQ 9 Meters Biopharma, Inc.
a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute ...
JPM 2025: WuXi AppTec rebuffs concern about lower GLP-1 demand after Lilly’s low revenue forecast
Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.